MX2024012392A - Terapia combinada para el tratamiento del cancer - Google Patents

Terapia combinada para el tratamiento del cancer

Info

Publication number
MX2024012392A
MX2024012392A MX2024012392A MX2024012392A MX2024012392A MX 2024012392 A MX2024012392 A MX 2024012392A MX 2024012392 A MX2024012392 A MX 2024012392A MX 2024012392 A MX2024012392 A MX 2024012392A MX 2024012392 A MX2024012392 A MX 2024012392A
Authority
MX
Mexico
Prior art keywords
treatment
cancer
combination therapy
combination
azd5305
Prior art date
Application number
MX2024012392A
Other languages
English (en)
Spanish (es)
Inventor
Sabina Chiara Cosulich
BROWN Jessica S
Albertella Mark R
Elisabetta Leo
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2024012392A publication Critical patent/MX2024012392A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2024012392A 2022-04-07 2024-10-04 Terapia combinada para el tratamiento del cancer MX2024012392A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263362613P 2022-04-07 2022-04-07
PCT/EP2023/059130 WO2023194530A1 (en) 2022-04-07 2023-04-06 Combination therapy for treating cancer

Publications (1)

Publication Number Publication Date
MX2024012392A true MX2024012392A (es) 2024-11-08

Family

ID=86226547

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024012392A MX2024012392A (es) 2022-04-07 2024-10-04 Terapia combinada para el tratamiento del cancer

Country Status (11)

Country Link
US (1) US20250213556A1 (https=)
EP (1) EP4504182A1 (https=)
JP (1) JP2025511402A (https=)
KR (1) KR20240170957A (https=)
CN (1) CN119212702A (https=)
AU (1) AU2023250031A1 (https=)
CA (1) CA3254949A1 (https=)
IL (1) IL316017A (https=)
MX (1) MX2024012392A (https=)
TW (1) TW202404661A (https=)
WO (1) WO2023194530A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202600137A (zh) * 2024-04-04 2026-01-01 美商輝瑞股份有限公司 於使用ｐａｒｐ抑制劑的治療作為預測性生物標記之ｔｍｐｒｓｓ２－ｅｒｇ和ｒｂｉ及使用ｐａｒｐ抑制劑之治療方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0705903B2 (en) 1994-08-12 2009-08-12 The University of Utah Research Foundation Mutations in the 17q-linked breast and ovarian cancer susceptibility gene
DK0699754T3 (da) 1994-08-12 2001-02-26 Myriad Genetics Inc Fremgangsmåde til diagnosticering af prædisposition for bryst- og ovariecancer
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
MX2022000711A (es) 2019-07-19 2022-02-23 Astrazeneca Ab Inhibidores de parp1.

Also Published As

Publication number Publication date
JP2025511402A (ja) 2025-04-15
KR20240170957A (ko) 2024-12-05
CA3254949A1 (en) 2023-10-12
IL316017A (en) 2024-11-01
EP4504182A1 (en) 2025-02-12
CN119212702A (zh) 2024-12-27
TW202404661A (zh) 2024-02-01
WO2023194530A1 (en) 2023-10-12
US20250213556A1 (en) 2025-07-03
AU2023250031A1 (en) 2024-11-14

Similar Documents

Publication Publication Date Title
NZ784224A (en) Parp1 inhibitors
CO2020015255A2 (es) Métodos y composiciones para tratar el cáncer
CO2020010956A2 (es) Composiciones y métodos para el tratamiento del cáncer y de trastornos inmunitarios usando bacterias de veillonella
CL2018001152A1 (es) Composiciones y métodos para el tratamiento del cáncer
AR102553A1 (es) Terapia de combinación con agonistas de unión ox40 e inhibidores de tigit
NI201900105A (es) Terapia combinada para el cáncer de próstata
CO2017007662A2 (es) Terapias de combinación para el tratamiento de cánceres
MX2023004156A (es) Terapia combinada para el tratamiento del cancer.
MX2023000549A (es) Combinaciones para el tratamiento de neoplasias usando localizacion de celulas quiescentes e inhibidores de egfr.
CL2017000317A1 (es) Terapia adjuntiva con 25-hidroxi vitamina d
CO2021004681A2 (es) Uso de reboxetina para el tratamiento de narcolepsia
MX2020001727A (es) Terapia de combinacion.
MX2019013862A (es) Terapia de combinacion.
AR119681A1 (es) Métodos de tratamiento del cáncer de mama con tucatinib
MX2024003918A (es) Agente terapeutico que induce citotoxicidad para usarse en terapia del cancer.
MX2024012392A (es) Terapia combinada para el tratamiento del cancer
PH12021551419A1 (en) New conjugated nucleic acid molecules and their uses
MX2021003263A (es) Combinacion de un antagonista de proteina de muerte programada 1 (pd-1), un inhibidor de ataxia telangiectasia y proteina relacionada con rad3 (atr) y un agente de platino para el tratamiento de cancer.
MX2024012368A (es) Terapia combinada para el tratamiento del cancer
CL2023003090A1 (es) Combinaciones de composiciones terapéuticas y usos para tratar cánceres
MX2022011845A (es) Terapia combinada con un inhibidor de idh mutante y un inhibidor de bcl-2.
CL2023002812A1 (es) Combinaciones farmacéuticas para el tratamiento del cáncer
MX2021011799A (es) Antagonistas de semaforina 4d para usarlos en la terapia contra el cancer.
JOP20220292A1 (ar) صياغات صيدلانية من أسيتات أبيراتيرون ونيراباريب
MX2021002884A (es) Terapia de combinacion para el tratamiento de cancer de prostata.